ALID (Allied) EBIT: $-3.07 Mil (TTM As of Nov. 2024)


What is Allied EBIT?

Allied ALID -99.80% EBIT is $-3.07 Mil as of Nov. 2024.

Allied's earnings before interest and taxes (EBIT) for the three months ended in Nov. 2024 was $-0.56 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Nov. 2024 was $-3.07 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Allied's annualized ROC % for the quarter that ended in Nov. 2024 was -26.02%. Allied's annualized ROC (Joel Greenblatt) % for the quarter that ended in Nov. 2024 was -167.93%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.


Allied  (OTCPK:ALID) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Allied's annualized ROC % for the quarter that ended in Nov. 2024 is calculated as:

ROC % (Q: Nov. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Aug. 2024 ) + Invested Capital (Q: Nov. 2024 ))/ count )
=-2.06 * ( 1 - 0% )/( (7.892 + 7.945)/ 2 )
=-2.06/7.9185
=-26.02 %

where

Note: The Operating Income data used here is four times the quarterly (Nov. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Allied's annualized ROC (Joel Greenblatt) % for the quarter that ended in Nov. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Nov. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Aug. 2024  Q: Nov. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-2.252/( ( (1.371 + max(-2.701, 0)) + (1.311 + max(-2.469, 0)) )/ 2 )
=-2.252/( ( 1.371 + 1.311 )/ 2 )
=-2.252/1.341
=-167.93 %

where Working Capital is:

Working Capital(Q: Aug. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.048 + 0.261 + 0.046) - (3.057 + 0 + -0.00099999999999945)
=-2.701

Working Capital(Q: Nov. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.071 + 0.287 + 0.054) - (2.881 + 0 + 0)
=-2.469

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Nov. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Allied's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Nov. 2024 )
=-3.065/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allied EBIT Related Terms


Allied EBIT Historical Data

* Premium members only.

The historical data trend for Allied's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allied EBIT Chart

Allied Annual Data
Trend Mar18 Mar19 Aug20 Aug21 Aug22 Aug23 Aug24
EBIT
Get a 7-Day Free Trial -6.46 -10.21 -14.30 -9.81 -3.13

Allied Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.63 -0.65 -0.68 -1.17 -0.56

ALID vs CBDY, PLSH, STEK: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allied's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allied EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Allied's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Allied's EV-to-EBIT falls into.



Allied EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Nov. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-3.07 Mil mean?
Allied (ALID) has a EBIT of $-3.07 Mil as of Nov. 2024. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Allied.
Is Allied's EBIT too high?
Allied's current EBIT is $-3.07 Mil.
How does Allied's EBIT compare to CBDY and PLSH?
Allied's EBIT of $-3.07 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Allied. Allied's current EBIT is $-3.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allied stock overvalued right now?
Allied (ALID) has a current EBIT of $-3.07 Mil. The current EBIT is $-3.07 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Allied (ALID), the current EBIT is $-3.07 Mil as of Nov. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allied Business Description

Address 460 Doyle Avenue, Suite 200, Kelowna, BC, CAN, V1Y OC2
Allied Corp is an international cannabis company with a mission to help people suffering from Post-Traumatic Stress Disorder (PTSD) by researching, creating, and producing targeted cannabinoid health solutions. The company uses an evidence-informed scientific approach to make this mission possible through cutting-edge pharmaceutical research and development, plant-based production, and the development of therapeutic products. The company operates in two segments, which include Allied and Allied Colombia. Its geographical segments consist of Colombia and Canada. The company's revenue is comprised of sales of cannabis products.